Investors in Corcept Therapeutics Urged to Act Before Key Deadline for Class Action Lawsuit

Investor Alert: Corcept Therapeutics Class Action

Recent news from national shareholder rights law firm Hagens Berman has placed a spotlight on Corcept Therapeutics Incorporated (NASDAQ: CORT). Investors with substantial losses are being encouraged to consider their involvement in a securities class action lawsuit, with a critical deadline fast approaching.

Key Details of the Case

The ongoing class action pertains to allegations that Corcept misrepresented information regarding its lead drug candidate, relacorilant. This has raised concerns about the company's transparency and its communications with the FDA.

Allegations of Concealment

Investors are urged to pay attention to the timeline of events from October 31, 2024, to December 30, 2025, during which material facts regarding the drug's approval process were allegedly withheld. Specifically, the complaint outlines a series of warnings issued by the FDA, which were not adequately disclosed to investors.

1. FDA Warnings: In several meetings held in 2024 and 2025, the FDA raised concerns about the lack of sufficient evidence supporting relacorilant's effectiveness.
2. Misleading Data: Despite understanding that the data from Phase 3 trials was flawed, Corcept continued to present it in a favorable light, misleading investors about the drug's actual potential for approval.
3. The Complete Response Letter (CRL): On December 31, 2025, Corcept disclosed that it had received a CRL from the FDA, stating that it could not conduct a favorable benefit-risk assessment due to an insufficient evidentiary record. This shocking announcement triggered a 50% drop in stock price, erasing nearly $2.5 billion in market capitalization within a single trading day.

Impact on Shareholders

As a result of the aforementioned issues, shareholders who purchased stock within the specified Class Period are facing significant losses and uncertainty regarding the stock’s recovery. Reed Kathrein, a partner at Hagens Berman, emphasized the stark division between what management appeared to communicate and the reality they understood regarding the likelihood of approval for relacorilant.

How to Join the Class Action

For those investors seeking to assert their claims, the deadline to act is fast approaching. To be appointed as the Lead Plaintiff in the class action, investors must submit their claims by April 21, 2026. Investors can find more information by visiting the dedicated CORT case page at Hagens Berman’s website.

Whistleblower Information

Additionally, whistleblowers who may possess non-public information relevant to the case are encouraged to come forward. Under the SEC Whistleblower program, they could earn rewards up to 30% of any successful recovery if their information proves beneficial.

Conclusion

With Corcept Therapeutics facing serious allegations and financial repercussions, it is essential for impacted investors to remain informed and proactive. The upcoming deadline for filing claims could be a pivotal moment for many shareholders affected by this situation. For detailed inquiries and assistance regarding the case, reach out to Hagens Berman at 844-916-0895 or email [email protected]

Stay updated on this developing situation by following Hagens Berman on social media and visiting their official website for further news and details.